email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

ISSN: 2643-6760

Surgery & Case Studies: Open Access Journal

Research Article(ISSN: 2643-6760)

Coexistence of A Secondary STRN-ALK EML4-ALK Double- Fusion Variant in A Lung Adenocarcinoma Patient with EGFR Mutation: A Case Report Volume 6 - Issue 1

Qian Zeng MD1, Han Gao MD2, Longan Zhang MD1, Shouming Qin BD2, Yongyao Gu MD3 and Quan Fang Chen MD2*

  • 1Department of Emergency, The First Affiliated Hospital, Guangxi Medical University, PR China
  • 2Institute of respiratory disease, The First Affiliated Hospital, Guangxi Medical University, PR China
  • 3Department of Pathology, The First Affiliated Hospital, Guangxi Medical University, PR China

Received: January 07, 2021;   Published: January 29, 2021

Corresponding author: Quan Fang Chen, Institute of Respiratory Disease, The First Affiliated Hospital Guangxi Medical University, No.6 Shuangyong Road, People’s Republic of China

DOI: 10.32474/SCSOAJ.2021.06.000229

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Anaplastic lymphoma kinase (ALK)-positive disease is characterized by the presence of ALK gene rearrangements that encode driver fusion oncoproteins. Echinoderm microtubule-associated protein-like 4 gene (EML4)-ALK fusion is regarded as the most common type and is reported in 2 to 7% of patients with advanced non–small cell lung cancers (NSCLCs). Striatin (STRN)-ALK is a novel ALK fusion partner in NSCLC and is considered sensitive to targeted therapy. However, there was no study regarding effective therapy for EML4-ALK and STRN-ALK double fusion variants in epidermal growth factor receptor (EGFR)-resistant mutant lung cancer. TP53, RB1, and EGFR exon 21 L858R were found in tumor tissues and plasma from patients with capture-based nextgeneration sequencing (NGS). After three months of gefitinib treatment, an NGS of plasma circulating tumor DNA (CTDNA) showed that all variants disappeared significantly, and the tumor mass regressed on computed tomography (CT). However, after 10 months, the patient developed drug resistance and the disease progressed with the appearance of new metastatic lesions in the liver and bones. A repeated NGS test revealed EGFR exon20 T790M and the appearance of a novel double-fusion EML4-ALK and STRNALK. A combined therapeutic regimen of crizotinib plus osimertinib showed a promising prognosis confirmed with lung CT scans showing stable lesion without any new metastasis. Moreover, a subsequent genotype by NGS also showed the disappearance of STRN-ALK and EGFR exon20 T790M. The therapeutic efficacy of crizotinib plus osimertinib on EML4-ALK and STRN-ALK doublefusion variant in patients with EGFR resistant mutant lung cancer may provide a supportive reference for the patients with such genetic alteration. NGS might contribute to optimizing the selection of patients.

Keywords: STRN-ALK; EML4-ALK; double-fusion; gefitinib; crizotinib; osimertinib

Abbreviations: ALK: Anaplastic Lymphoma Kinase; EML4: Echinoderm Microtubule-Associated Protein-like 4 gene; NSCLC: Non–Small Cell Lung Cancer; STRN: Striatin; EGFR: Epidermal Growth Factor Receptor; NGS: Next-Generation Sequencing; CTDNA: Circulating Tumor DNA CT: Computed Tomography; TKI: Tyrosine Kinase Inhibitors

Abstract| Introduction| Case Presentation| Discussion| Conclusion| References|

Close

Online Submission System

Drag and drop files here

or

Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )